We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cerep and Servier Establish a new Collaboration Agreement for Drug Discovery and Lead Optimization
News

Cerep and Servier Establish a new Collaboration Agreement for Drug Discovery and Lead Optimization

Cerep and Servier Establish a new Collaboration Agreement for Drug Discovery and Lead Optimization
News

Cerep and Servier Establish a new Collaboration Agreement for Drug Discovery and Lead Optimization

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cerep and Servier Establish a new Collaboration Agreement for Drug Discovery and Lead Optimization"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cerep announces the signature with Servier of a 3-year collaboration agreement for the discovery and optimization of new drugs. The terms of the agreement provide that Servier will identify targets of interest and will transfer to Cerep its collection of compounds.

Cerep will be responsible for the development and validation of the corresponding pharmacological assays and will run high throughput screenings on Servier library.

As part of this agreement, Cerep will also profile hit compounds identified during the high throughput screening campaigns as well as the drug candidates optimized for the selected target. Screening and profiling data will be made available in real time through the secured web access system Data OnLine developed by Cerep.

In addition, Servier will have access to BioPrint® services for an improved interpretation of in vitro data and for a better selection of drug candidates with less potential side effects and optimized safety profile.

Financial terms of the agreement are undisclosed; they include a monthly payment during the 3 years of the collaboration. Thierry Jean, Chairman and CEO of Cerep, commented: "Servier is an historical partner of Cerep and we have continuously entertained excellent relationships. We are particularly happy to sign a new collaboration which illustrates the high level of confidence and respect shared by the two companies."

Emmanuel Canet, President of Research and Development of Servier, declared: "With this agreement, Servier takes a new step in its contribution to medical progress and therapeutic innovation and confirms its commitment to collaborate with innovative biotech and research companies in France."

Bernard Marchand, Research Director at Servier, added: "With its experience in the development of new pharmacological assays, its organization and expertise in compound management and screening, but also the access to its BioPrint® database and tools, Cerep is a partner of choice for our new drug discovery research programs."
Advertisement